版本:
中国

BRIEF-Cellectar’s radiotherapeutic PDCS demonstrate increased survival benefit using multiple doses

April 27 Cellectar Biosciences Inc:

* Cellectar’s radiotherapeutic PDCS demonstrate an increased survival benefit using multiple doses in preclinical studies

* Cellectar Biosciences Inc - pancreatic cancer model demonstrates potential utility of clr 131 in solid tumors

* Cellectar Biosciences Inc - data from both of solid tumor animal studies indicate multiple doses of radiotherapeutic pdc resulted in increased survival benefit over single dose Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐